尔康制药
(300267)
| 流通市值：45.66亿 | | | 总市值：66.21亿 |
| 流通股本：14.22亿 | | | 总股本：20.63亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 353,547,866.17 | 1,139,612,276.29 | 854,289,240.97 | 621,346,708.93 |
| 营业收入 | 353,547,866.17 | 1,139,612,276.29 | 854,289,240.97 | 621,346,708.93 |
| 二、营业总成本 | 338,072,474.37 | 1,213,768,146.03 | 893,553,175.63 | 626,817,368.29 |
| 营业成本 | 261,148,226.49 | 825,958,465.34 | 589,956,713.99 | 432,636,194.26 |
| 税金及附加 | 3,493,070.86 | 16,670,464.22 | 12,546,127.42 | 9,034,868.81 |
| 销售费用 | 8,128,608.81 | 99,644,171.46 | 72,760,892.14 | 48,118,814.41 |
| 管理费用 | 54,188,849.7 | 226,034,547.54 | 186,072,967.17 | 117,468,875.24 |
| 研发费用 | 9,935,801.85 | 45,170,389.39 | 34,116,241.19 | 21,195,856.15 |
| 财务费用 | 1,177,916.66 | 290,108.08 | -1,899,766.28 | -1,637,240.58 |
| 其中:利息费用 | 2,731,240.92 | 9,331,116.15 | 8,260,001.63 | 6,264,017.61 |
| 其中:利息收入 | 933,387.34 | 4,734,525.34 | 3,812,953.16 | 2,926,397.32 |
| 加:公允价值变动收益 | - | 419,800 | 302,800 | 419,800 |
| 加:投资收益 | 2,661,106.84 | -55,831,057.55 | 1,197,544.78 | 935,164.92 |
| 资产处置收益 | -42,801.59 | 198,252.71 | 172,802.09 | - |
| 资产减值损失(新) | -181,352.27 | -261,206,368.61 | -339,139.89 | 849,381.88 |
| 信用减值损失(新) | 5,671,076.98 | 70,429.94 | 776,616.71 | 2,223,666.55 |
| 其他收益 | 2,644,876.88 | 19,896,736.03 | 16,853,806.95 | 12,777,360.78 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 26,228,298.64 | -370,608,077.22 | -20,299,504.02 | 11,734,714.77 |
| 加:营业外收入 | 479,839.6 | 831,282.11 | 348,987.15 | 328,560.28 |
| 减:营业外支出 | 121,253.7 | 18,341,011.16 | 3,746,966.71 | 3,428,410.5 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 26,586,884.54 | -388,117,806.27 | -23,697,483.58 | 8,634,864.55 |
| 减:所得税费用 | 2,644,841.35 | 4,509,066.4 | 3,192,221.12 | 2,296,527.9 |
| 六、净利润 | 23,942,043.19 | -392,626,872.67 | -26,889,704.7 | 6,338,336.65 |
| 持续经营净利润 | 23,942,043.19 | -392,626,872.67 | -26,889,704.7 | 6,338,336.65 |
| 归属于母公司股东的净利润 | 28,112,585.22 | -373,371,435.91 | -25,467,316.32 | 6,300,155.19 |
| 少数股东损益 | -4,170,542.03 | -19,255,436.76 | -1,422,388.38 | 38,181.46 |
| (一)基本每股收益 | 0.01 | -0.18 | -0.01 | 0 |
| (二)稀释每股收益 | 0.01 | -0.18 | -0.01 | 0 |
| 八、其他综合收益 | -11,550,621.21 | -15,464,320.82 | -85,012,752.5 | -38,766,130.01 |
| 归属于母公司股东的其他综合收益 | -11,467,886.08 | -15,519,629.2 | -84,977,701.27 | -38,800,161.2 |
| 九、综合收益总额 | 12,391,421.98 | -408,091,193.49 | -111,902,457.2 | -32,427,793.36 |
| 归属于母公司股东的综合收益总额 | 16,644,699.14 | -388,891,065.11 | -110,445,017.59 | -32,500,006.01 |
| 归属于少数股东的综合收益总额 | -4,253,277.16 | -19,200,128.38 | -1,457,439.61 | 72,212.65 |
| 公告日期 | 2025-04-23 | 2025-04-23 | 2024-10-25 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |